Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.73 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.70 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | APEX1 | P27695 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351641 | 0.98 | ATM (1.00) | ATMKDM4ELMNATAAR1GLA | |
| SCHEMBL210639 | 0.98 | ATM (1.00) | ATMKDM4ELMNATAAR1GLA | |
| Iodide SCHEMBL10518637 | 0.96 | ATM (0.96) | ATMKDM4ELMNATAAR1GLA | |
| Bromide SCHEMBL11470661 | 0.96 | ATM (0.96) | ATMKDM4ELMNATAAR1GLA | |
| Hydrochloric Acid SCHEMBL29963499 | 0.91 | ATM (0.80) | ATMKDM4ELMNATAAR1GLA | |
| SCHEMBL2755530 | 0.89 | ATM (0.83) | ATMKDM4ELMNATAAR1GLA | |
| Bicarbonate SCHEMBL11577791 | 0.89 | ATM (0.83) | ATMKDM4ELMNATAAR1GLA | |
| Hydrochloric Acid SCHEMBL27160305 | 0.88 | KDM4E (0.74) | ATMKDM4ELMNATAAR1GLA | |
| Hydrochloric Acid SCHEMBL29963614 | 0.88 | KDM4E (0.74) | ATMKDM4ELMNATAAR1GLA | |
| SCHEMBL14578752 | 0.87 | ATM (0.79) | ATMKDM4ELMNATAAR1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082547-A1 | METHOD FOR SYNTHESIZING DOPAMINE HYDROCHLORIDE FROM EUGENOL | 中国科学院广州能源研究所 | 2025-04-24 | — | — | WO | claimed |
| CN-118771991-A | Method for synthesizing dopamine hydrochloride from eugenol | 中国科学院广州能源研究所 | 2024-10-15 | — | — | CN | claimed |
| CN-121873068-A | Preparation method of berberine hydrochloride | 西安方昊化工有限公司 | 2026-04-17 | — | — | CN | disclosed |
| EP-4609864-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ISOQUINOLINONE COMPOUND, AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| EP-4610257-A1 | CRYSTAL FORM OF ISOQUINOLINONE COMPOUND AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| CN-119923263-A | Pharmaceutical composition containing isoquinolinones and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025082547-A1 | METHOD FOR SYNTHESIZING DOPAMINE HYDROCHLORIDE FROM EUGENOL | 中国科学院广州能源研究所 | 2025-04-24 | — | — | WO | disclosed |
| CN-118771991-A | Method for synthesizing dopamine hydrochloride from eugenol | 中国科学院广州能源研究所 | 2024-10-15 | — | — | CN | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024088402-A1 | CRYSTAL FORM OF ISOQUINOLINONE COMPOUND AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2024-05-02 | — | — | WO | disclosed |
| WO-2024088364-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ISOQUINOLINONE COMPOUND, AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2024-05-02 | — | — | WO | disclosed |
| WO-2000040552-A1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| US-5223510-A | ALKYLAMINOALKYL DERIVATIVES OF BENZOFURAN, BENZOTHIOPHENE, INDOLE AND INDOLIZINE, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1993-06-29 | — | — | US | disclosed |
| US-4994618-A | Bevantolol preparation | WARNER-LAMBERT COMPANY (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0165682-B1 | THE PREPARATION OF 1-(3,4-DIMETHOXYPHENETHYL AMINO)-3-(SUBSTITUTED PHENOXY)-2-PROPANOLS | WARNER-LAMBERT COMPANY (US) | 1988-06-29 | — | — | EP | disclosed |
| EP-0165682-A1 | The preparation of 1-(3,4-dimethoxyphenethyl amino)-3-(substituted phenoxy)-2-propanols | WARNER-LAMBERT COMPANY (US) | 1985-12-27 | — | — | EP | disclosed |
| EP-0086256-B1 | 1-(2,4-DICHLOROPHENOXY)-3-(3,4-DIMETHOXY-BETA-PHENETHYLAMINO)-PROPAN-2-0L, PROCESSES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | VEB Arzneimittelwerk Dresden (DD) | 1985-08-21 | — | — | EP | disclosed |
| US-4443468-A | ANTIDYSRHYTHMIA AGENTS, CARDIOVASCULAR DISORDERS | LABORATOIRES JACQUES LOGEAIS (FR) | 1984-04-17 | — | — | US | disclosed |
| EP-0086256-A1 | 1-(2,4-Dichlorophenoxy)-3-(3,4-dimethoxy-beta-phenethylamino)-propan-2-0l, processes for its preparation and pharmaceutical compositions containing it | VEB Arzneimittelwerk Dresden (DD) | 1983-08-24 | — | — | EP | disclosed |
| US-4339384-A | ANTIARRHYTHMIA AGENTS | LABORATOIRES JACQUES LOGEAIS (FR) | 1982-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | CYP4A11, CYP11B2, NQO1 | GLA 4316/4885CYP19A1 10/4885CA2 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.